{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:54:38Z","timestamp":1793861678026,"version":"4.6.1"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"DOI":"10.1038\/s41571-026-01213-3","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:01:13Z","timestamp":1791532873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A modular framework for antibody\u2013drug conjugate biomarkers"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-6516","authenticated-orcid":false,"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Yun","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"McNamee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6302-6107","authenticated-orcid":false,"given":"Roger R.","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Xiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-4397","authenticated-orcid":false,"given":"David L.","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-7199","authenticated-orcid":false,"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"1213_CR1","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & de Vries, E. G. E. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 14, 2089\u20132108 https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0708 (2024).","journal-title":"Cancer Discov."},{"key":"1213_CR2","doi-asserted-by":"publisher","first-page":"e00225","DOI":"10.1042\/BSR20150089","volume":"35","author":"C Peters","year":"2015","unstructured":"Peters, C. & Brown, S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep. 35, e00225 https:\/\/doi.org\/10.1042\/BSR20150089 (2015).","journal-title":"Biosci. Rep."},{"key":"1213_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/1078-0432.CCR-25-3103","volume":"32","author":"NJ McNamee","year":"2026","unstructured":"McNamee, N. J., Liu, J., Poulos, R. C., Aref, A. T. & Reddel, R. R. Predictive biomarkers of antibody-drug conjugate efficacy for solid tumors: current challenges and the potential role of quantitative proteomics. Clin. Cancer Res. 32, 661\u2013673 https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-3103 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327\u2013344 https:\/\/doi.org\/10.1038\/s41571-021-00470-8 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1213_CR5","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO-25-01235","volume":"43","author":"M Vogel","year":"2025","unstructured":"Vogel, M., Colombo, R. & Tarantino, P. Beyond the guided missile paradigm: embracing the complexity of antibody-drug conjugates. J. Clin. Oncol. 43, 3339\u20133344 https:\/\/doi.org\/10.1200\/JCO-25-01235 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1213_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41417-023-00701-3","volume":"31","author":"J Fang","year":"2024","unstructured":"Fang, J. et al. The target atlas for antibody-drug conjugates across solid cancers. Cancer Gene Ther. 31, 273\u2013284 https:\/\/doi.org\/10.1038\/s41417-023-00701-3 (2024).","journal-title":"Cancer Gene Ther."},{"key":"1213_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47\u201358 https:\/\/doi.org\/10.1200\/JCO.23.02005 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1213_CR8","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1200\/JCO-26-00034","volume":"44","author":"J Liu","year":"2026","unstructured":"Liu, J. et al. Tumor-agnostic therapies: translating scientific breakthroughs into global implementation. J. Clin. Oncol. 44, 1933\u20131944 https:\/\/doi.org\/10.1200\/JCO-26-00034 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1213_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100032","volume":"36","author":"CJ Robbins","year":"2023","unstructured":"Robbins, C. J. et al. Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry. Mod. Pathol. 36, 100032 https:\/\/doi.org\/10.1016\/j.modpat.2022.100032 (2023).","journal-title":"Mod. Pathol."},{"key":"1213_CR10","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1158\/1078-0432.CCR-25-3321","volume":"32","author":"DR Rampa","year":"2026","unstructured":"Rampa, D. R. et al. Payload diversification overcomes resistance and guides sequential antibody-drug conjugate therapy in breast cancer. Clin. Cancer Res. 32, 1454\u20131461 https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-3321 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00748-5","volume":"11","author":"LA Huppert","year":"2025","unstructured":"Huppert, L. A. et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). NPJ Breast Cancer 11, 34 https:\/\/doi.org\/10.1038\/s41523-025-00748-5 (2025).","journal-title":"NPJ Breast Cancer"},{"key":"1213_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00898","volume":"9","author":"N Mai","year":"2025","unstructured":"Mai, N. et al. Sequential antibody-drug conjugate therapy in patients with metastatic breast cancer treated with sacituzumab govitecan and trastuzumab deruxtecan. JCO Precis. Oncol. 9, e2400898 https:\/\/doi.org\/10.1200\/PO-24-00898 (2025).","journal-title":"JCO Precis. Oncol."},{"key":"1213_CR13","doi-asserted-by":"publisher","first-page":"107604","DOI":"10.1016\/j.esmoop.2026.107604","volume":"11","author":"P Tarantino","year":"2026","unstructured":"Tarantino, P. et al. LBA4 Efficacy and safety of sacituzumab govitecan (SG) plus trastuzumab in patients with HER2+ metastatic breast cancer after prior trastuzumab deruxtecan (T-DXd): results from the phase II SATEEN trial. ESMO Open 11, 107604 https:\/\/doi.org\/10.1016\/j.esmoop.2026.107604 (2026).","journal-title":"ESMO Open"},{"key":"1213_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.04.008","author":"R Colombo","year":"2026","unstructured":"Colombo, R., Seredick, S., Barnscher, S. D. & Rich, J. R. Re-evaluating antibody-drug conjugate linker stability: assessment, interpretation, and clinical translation. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2026.04.008 (2026).","journal-title":"Ann. Oncol."},{"key":"1213_CR15","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ccell.2026.05.004","volume":"44","author":"B Pistilli","year":"2026","unstructured":"Pistilli, B., Colombo, R., Mosele, M. F. & Chandarlapaty, S. Antibody-drug conjugates in precision oncology. Cancer Cell 44, 1126\u20131146 https:\/\/doi.org\/10.1016\/j.ccell.2026.05.004 (2026).","journal-title":"Cancer Cell"},{"key":"1213_CR16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","volume":"25","author":"A Zippelius","year":"2025","unstructured":"Zippelius, A., Tolaney, S. M., Tarantino, P., Balthasar, J. P. & Thurber, G. M. Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment. Nat. Rev. Cancer 25, 925\u2013944 https:\/\/doi.org\/10.1038\/s41568-025-00869-w (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"1213_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"LC Tsao","year":"2025","unstructured":"Tsao, L. C. et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat. Commun. 16, 3167 https:\/\/doi.org\/10.1038\/s41467-025-58266-8 (2025).","journal-title":"Nat. Commun."},{"key":"1213_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","volume":"138","author":"AC Wolff","year":"2014","unstructured":"Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. Arch. Pathol. Lab. Med. 138, 241\u2013256 https:\/\/doi.org\/10.5858\/arpa.2013-0953-SA (2014).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1213_CR19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41571-025-01016-y","volume":"22","author":"CJ Robbins","year":"2025","unstructured":"Robbins, C. J., Bates, K. M. & Rimm, D. L. HER2 testing: evolution and update for a companion diagnostic assay. Nat. Rev. Clin. Oncol. 22, 408\u2013423 https:\/\/doi.org\/10.1038\/s41571-025-01016-y (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1213_CR20","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino, P. et al. HER2-low breast cancer: pathological and clinical landscape. J. Clin. Oncol. 38, 1951\u20131962 https:\/\/doi.org\/10.1200\/JCO.19.02488 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1213_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.5858\/arpa.2024-0052-OA","volume":"149","author":"J Ruschoff","year":"2025","unstructured":"Ruschoff, J. et al. Global study on the accuracy of human epidermal growth factor receptor 2-low diagnosis in breast cancer. Arch. Pathol. Lab. Med. 149, 431\u2013438 https:\/\/doi.org\/10.5858\/arpa.2024-0052-OA (2025).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1213_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-026-01365-6","volume":"10","author":"P Tarantino","year":"2026","unstructured":"Tarantino, P. et al. Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer. NPJ Precis. Oncol. 10, 141 https:\/\/doi.org\/10.1038\/s41698-026-01365-6 (2026).","journal-title":"NPJ Precis. Oncol."},{"key":"1213_CR23","first-page":"716","volume":"109","author":"KS McCarty Jr.","year":"1985","unstructured":"McCarty, K. S. Jr., Miller, L. S., Cox, E. B., Konrath, J. & McCarty, K. S. Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 109, 716\u2013721 (1985).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1213_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/jcp.48.9.876","volume":"48","author":"S Detre","year":"1995","unstructured":"Detre, S., Saclani Jotti, G. & Dowsett, M. A \u201cquickscore\u201d method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J. Clin. Pathol. 48, 876\u2013878 https:\/\/doi.org\/10.1136\/jcp.48.9.876 (1995).","journal-title":"J. Clin. Pathol."},{"key":"1213_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/PAI.0000000000001311","volume":"34","author":"M He","year":"2026","unstructured":"He, M. et al. Quantitative assays for TROP2 measurement in breast cancer and comparison to H-sscore. Appl. Immunohistochem. Mol. Morphol. 34, 143\u2013154 https:\/\/doi.org\/10.1097\/PAI.0000000000001311 (2026).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"1213_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1078-0432.CCR-24-1007","volume":"31","author":"M Rediti","year":"2025","unstructured":"Rediti, M. et al. Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine: an analysis of the ZEPHIR clinical trial. Clin. Cancer Res. 31, 110\u2013121 https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1007 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00610-6","volume":"10","author":"M Mileva","year":"2024","unstructured":"Mileva, M. et al. Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial). NPJ Breast Cancer 10, 4 https:\/\/doi.org\/10.1038\/s41523-023-00610-6 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"1213_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/annonc\/mdv577","volume":"27","author":"G Gebhart","year":"2016","unstructured":"Gebhart, G. et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann. Oncol. 27, 619\u2013624 https:\/\/doi.org\/10.1093\/annonc\/mdv577 (2016).","journal-title":"Ann. Oncol."},{"key":"1213_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the Rosetta Stone of therapy resistance. Cancer Cell 37, 471\u2013484 https:\/\/doi.org\/10.1016\/j.ccell.2020.03.007 (2020).","journal-title":"Cancer Cell"},{"key":"1213_CR30","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. 29, 2110\u20132120 https:\/\/doi.org\/10.1038\/s41591-023-02478-2 (2023).","journal-title":"Nat. Med."},{"key":"1213_CR31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2025.03.017","volume":"43","author":"D Ma","year":"2025","unstructured":"Ma, D. et al. Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. Cancer Cell 43, 1061\u20131075 e1067 https:\/\/doi.org\/10.1016\/j.ccell.2025.03.017 (2025).","journal-title":"Cancer Cell"},{"key":"1213_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00927-4","volume":"9","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Biopsy image-based deep learning for predicting pathologic response to neoadjuvant chemotherapy in patients with NSCLC. NPJ Precis. Oncol. 9, 132 https:\/\/doi.org\/10.1038\/s41698-025-00927-4 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"1213_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01107-0","volume":"9","author":"J Lesniak","year":"2025","unstructured":"Lesniak, J. et al. Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC. NPJ Precis. Oncol. 9, 315 https:\/\/doi.org\/10.1038\/s41698-025-01107-0 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"1213_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61957-9","volume":"14","author":"A Kapil","year":"2024","unstructured":"Kapil, A. et al. HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer. Sci. Rep. 14, 12129 https:\/\/doi.org\/10.1038\/s41598-024-61957-9 (2024).","journal-title":"Sci. Rep."},{"key":"1213_CR35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-26-0093","author":"N Klumper","year":"2026","unstructured":"Klumper, N. et al. Integrating NECTIN4 amplification with membranous nectin-4 expression to develop a scoring system for predicting enfortumab vedotin response in urothelial carcinoma. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.ccr-26-0093 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2026.03.017","author":"D Planchard","year":"2026","unstructured":"Planchard, D. et al. Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2026.03.017 (2026).","journal-title":"Cancer Cell"},{"key":"1213_CR37","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","volume":"19","author":"MC Garassino","year":"2024","unstructured":"Garassino, M. C. et al. PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-lung 01. J. Thorac. Oncol. 19, S2\u2013S3 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"1213_CR38","doi-asserted-by":"publisher","first-page":"S212","DOI":"10.1016\/S1556-0864(25)00549-0","volume":"20","author":"Y-L Wu","year":"2025","unstructured":"Wu, Y.-L. et al. 357P: Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced\/metastatic non-small cell lung cancer (a\/mNSCLC) treated with datopotamab deruxtecan (Dato-DXd) in TROPION-PanTumor02. J. Thorac. Oncol. 20, S212\u2013S213 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"1213_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2026.103688","volume":"21","author":"B Levy","year":"2026","unstructured":"Levy, B. et al. Datopotamab deruxtecan plus pembrolizumab with or without platinum-based chemotherapy for advanced or metastatic NSCLC: the phase Ib TROPION-Lung02 trial. J. Thorac. Oncol. 21, 103688 https:\/\/doi.org\/10.1016\/j.jtho.2026.103688 (2026).","journal-title":"J. Thorac. Oncol."},{"key":"1213_CR40","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07291037 (2026)."},{"key":"1213_CR41","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ccell.2026.04.010","volume":"44","author":"Y Wang","year":"2026","unstructured":"Wang, Y. et al. Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer. Cancer Cell 44, 1201\u20131217.e7 https:\/\/doi.org\/10.1016\/j.ccell.2026.04.010 (2026).","journal-title":"Cancer Cell"},{"key":"1213_CR42","doi-asserted-by":"publisher","first-page":"e012683","DOI":"10.1136\/jitc-2025-012683","volume":"13","author":"SH Lim","year":"2025","unstructured":"Lim, S. H. et al. Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy. J. Immunother. Cancer 13, e012683 https:\/\/doi.org\/10.1136\/jitc-2025-012683 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1213_CR43","doi-asserted-by":"publisher","first-page":"LBA458","DOI":"10.1158\/1538-7445.AM2025-LB458","volume":"85","author":"M Martin","year":"2025","unstructured":"Martin, M. et al. Abstract LB458: Osimertinib treatment drives expression of TROP2, and combination treatment with datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, enhances its efficacy in PDX models of EGFR mutant non small-cell lung cancer. Cancer Res. 85, LBA458 (2025).","journal-title":"Cancer Res."},{"key":"1213_CR44","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/2159-8290.CD-24-1515","volume":"15","author":"S Baldacci","year":"2025","unstructured":"Baldacci, S. et al. Eradicating drug-tolerant persister cells in EGFR-mutated non-small cell lung cancer by targeting TROP2 with CAR-T cellular therapy. Cancer Discov. 15, 2235\u20132250 https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1515 (2025).","journal-title":"Cancer Discov."},{"key":"1213_CR45","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.annonc.2026.02.014","volume":"37","author":"JW Riess","year":"2026","unstructured":"Riess, J. W. et al. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD. Ann. Oncol. 37, 825\u2013836 https:\/\/doi.org\/10.1016\/j.annonc.2026.02.014 (2026).","journal-title":"Ann. Oncol."},{"key":"1213_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","volume":"16","author":"W Chen","year":"2026","unstructured":"Chen, W. et al. Trastuzumab deruxtecan resistance via loss of HER2 expression and binding. Cancer Discov. 16, 235\u2013249 https:\/\/doi.org\/10.1158\/2159-8290.CD-25-0647 (2026).","journal-title":"Cancer Discov."},{"key":"1213_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00343-4","volume":"7","author":"F Miglietta","year":"2021","unstructured":"Miglietta, F. et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer 7, 137 https:\/\/doi.org\/10.1038\/s41523-021-00343-4 (2021).","journal-title":"NPJ Breast Cancer"},{"key":"1213_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115648","volume":"224","author":"GB Armstrong","year":"2025","unstructured":"Armstrong, G. B. et al. Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers. Adv. Drug Deliv. Rev. 224, 115648 https:\/\/doi.org\/10.1016\/j.addr.2025.115648 (2025).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1213_CR49","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","volume":"66","author":"HK Erickson","year":"2006","unstructured":"Erickson, H. K. et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66, 4426\u20134433 https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4489 (2006).","journal-title":"Cancer Res."},{"key":"1213_CR50","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","volume":"14","author":"R Sheyi","year":"2022","unstructured":"Sheyi, R., de la Torre, B. G. & Albericio, F. Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics 14, 396 https:\/\/doi.org\/10.3390\/pharmaceutics14020396 (2022).","journal-title":"Pharmaceutics"},{"key":"1213_CR51","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1021\/acs.bioconjchem.7b00304","volume":"28","author":"A Dal Corso","year":"2017","unstructured":"Dal Corso, A., Cazzamalli, S., Gebleux, R., Mattarella, M. & Neri, D. Protease-cleavable linkers modulate the anticancer activity of noninternalizing antibody-drug conjugates. Bioconjug. Chem. 28, 1826\u20131833 https:\/\/doi.org\/10.1021\/acs.bioconjchem.7b00304 (2017).","journal-title":"Bioconjug. Chem."},{"key":"1213_CR52","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/psp4.13133","volume":"13","author":"C Vasalou","year":"2024","unstructured":"Vasalou, C. et al. Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression. CPT Pharmacomet. Syst. Pharmacol. 13, 994\u20131005 https:\/\/doi.org\/10.1002\/psp4.13133 (2024).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"1213_CR53","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jconrel.2017.08.040","volume":"264","author":"A Dal Corso","year":"2017","unstructured":"Dal Corso, A., Gebleux, R., Murer, P., Soltermann, A. & Neri, D. A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo. J. Control. Rel. 264, 211\u2013218 https:\/\/doi.org\/10.1016\/j.jconrel.2017.08.040 (2017).","journal-title":"J. Control. Rel."},{"key":"1213_CR54","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-17-2391","volume":"77","author":"NG Caculitan","year":"2017","unstructured":"Caculitan, N. G. et al. Cathepsin B is dispensable for cellular processing of cathepsin B-cleavable antibody-drug conjugates. Cancer Res. 77, 7027\u20137037 https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2391 (2017).","journal-title":"Cancer Res."},{"key":"1213_CR55","doi-asserted-by":"publisher","first-page":"PS2-08-18","DOI":"10.1158\/1557-3265.SABCS25-PS2-08-18","volume":"34","author":"S Alkassis","year":"2026","unstructured":"Alkassis, S. et al. Abstract PS2-08-18: cathepsin protease expression and therapeutic outcomes to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. Clin. Cancer Res. 34, PS2-08-18 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR56","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1158\/1535-7163.MCT-14-0881-T","volume":"14","author":"MM van der Lee","year":"2015","unstructured":"van der Lee, M. M. et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol. Cancer Ther. 14, 692\u2013703 https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0881-T (2015).","journal-title":"Mol. Cancer Ther."},{"key":"1213_CR57","doi-asserted-by":"publisher","first-page":"25798","DOI":"10.1021\/acsomega.0c03102","volume":"5","author":"B Min","year":"2020","unstructured":"Min, B. et al. cIRCR201-dPBD, a novel pyrrolobenzodiazepine dimer-containing site-specific antibody-drug conjugate targeting c-met overexpression tumors. ACS Omega 5, 25798\u201325809 https:\/\/doi.org\/10.1021\/acsomega.0c03102 (2020).","journal-title":"ACS Omega"},{"key":"1213_CR58","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","volume":"22","author":"A Kopp","year":"2023","unstructured":"Kopp, A. et al. Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release. Mol. Cancer Ther. 22, 102\u2013111 https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0375 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"1213_CR59","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen, T. D., Bordeau, B. M. & Balthasar, J. P. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers 15, 713 https:\/\/doi.org\/10.3390\/cancers15030713 (2023).","journal-title":"Cancers"},{"key":"1213_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103067","volume":"142","author":"LFC de Almeida","year":"2026","unstructured":"de Almeida, L. F. C. et al. Sequencing antibody-drug conjugates in metastatic breast cancer: a systematic review. Cancer Treat. Rev. 142, 103067 https:\/\/doi.org\/10.1016\/j.ctrv.2025.103067 (2026).","journal-title":"Cancer Treat. Rev."},{"key":"1213_CR61","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1093\/oncolo\/oyae055","volume":"29","author":"M Chen","year":"2024","unstructured":"Chen, M. et al. Optimal sequential strategies for antibody-drug conjugate in metastatic breast cancer: evaluating efficacy and cross-resistance. Oncologist 29, e957\u2013e966 https:\/\/doi.org\/10.1093\/oncolo\/oyae055 (2024).","journal-title":"Oncologist"},{"key":"1213_CR62","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22, 5097\u20135108 https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR63","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","volume":"26","author":"TM Cardillo","year":"2015","unstructured":"Cardillo, T. M. et al. Sacituzumab govitecan (IMMU-132), an anti-trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug. Chem. 26, 919\u2013931 https:\/\/doi.org\/10.1021\/acs.bioconjchem.5b00223 (2015).","journal-title":"Bioconjug. Chem."},{"key":"1213_CR64","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates, J. T. et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 11, 2436\u20132445 https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0702 (2021).","journal-title":"Cancer Discov."},{"key":"1213_CR65","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","volume":"31","author":"RO Abelman","year":"2025","unstructured":"Abelman, R. O. et al. TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer. Clin. Cancer Res. 31, 1966\u20131974 https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2771 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR66","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey, R. W. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 18, 452\u2013464 https:\/\/doi.org\/10.1038\/s41568-018-0005-8 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1213_CR67","doi-asserted-by":"publisher","first-page":"2","DOI":"10.20517\/cdr.2025.151","volume":"9","author":"JS Roth","year":"2026","unstructured":"Roth, J. S. et al. Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters. Cancer Drug Resist. 9, 2 https:\/\/doi.org\/10.20517\/cdr.2025.151 (2026).","journal-title":"Cancer Drug Resist."},{"key":"1213_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00868-y","volume":"12","author":"GW Sledge","year":"2025","unstructured":"Sledge, G. W. et al. Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling. NPJ Breast Cancer 12, 1 https:\/\/doi.org\/10.1038\/s41523-025-00868-y (2025).","journal-title":"NPJ Breast Cancer"},{"key":"1213_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106113","volume":"11","author":"L Basmpana","year":"2026","unstructured":"Basmpana, L., Petousis, S., Margioula-Siarkou, C. & Dinas, K. 10P Payload-centric determinants of sustained benefit from HER3-DXd and other TOP1-inhibitor ADCs in breast cancer: a systematic review of clinical, translational and preclinical evidence. ESMO Open 11, 106113 https:\/\/doi.org\/10.1016\/j.esmoop.2026.106113 (2026).","journal-title":"ESMO Open"},{"key":"1213_CR70","doi-asserted-by":"publisher","first-page":"15030","DOI":"10.1073\/pnas.1205943109","volume":"109","author":"G Zoppoli","year":"2012","unstructured":"Zoppoli, G. et al. Putative DNA\/RNA helicase schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc. Natl Acad. Sci. USA 109, 15030\u201315035 https:\/\/doi.org\/10.1073\/pnas.1205943109 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1213_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1582738","volume":"15","author":"K Zhou","year":"2025","unstructured":"Zhou, K. et al. SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance. Front. Oncol. 15, 1582738 https:\/\/doi.org\/10.3389\/fonc.2025.1582738 (2025).","journal-title":"Front. Oncol."},{"key":"1213_CR72","first-page":"3010","volume":"56","author":"WT Beck","year":"1996","unstructured":"Beck, W. T. et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients\u2019 tumors: consensus recommendations. Cancer Res. 56, 3010\u20133020 (1996).","journal-title":"Cancer Res."},{"key":"1213_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113854","volume":"176","author":"N Batis","year":"2021","unstructured":"Batis, N. et al. Lack of predictive tools for conventional and targeted cancer therapy: barriers to biomarker development and clinical translation. Adv. Drug Deliv. Rev. 176, 113854 https:\/\/doi.org\/10.1016\/j.addr.2021.113854 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1213_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38032-4","volume":"14","author":"T Yoshino","year":"2023","unstructured":"Yoshino, T. et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat. Commun. 14, 3332 https:\/\/doi.org\/10.1038\/s41467-023-38032-4 (2023).","journal-title":"Nat. Commun."},{"key":"1213_CR75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.4508","author":"G Iyer","year":"2026","unstructured":"Iyer, G. et al. 4508: Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.4508 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1213_CR76","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1158\/1535-7163.MCT-25-0271","volume":"25","author":"P Ren","year":"2026","unstructured":"Ren, P. et al. A novel dual-payload ADC platform integrating exatecan and triptolide to enhance antitumor efficacy and overcome resistance. Mol. Cancer Ther. 25, 529\u2013540 https:\/\/doi.org\/10.1158\/1535-7163.MCT-25-0271 (2026).","journal-title":"Mol. Cancer Ther."},{"key":"1213_CR77","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama, K., Anami, Y., Ha, S. Y. Y. & Yamazaki, C. M. Exploring the next generation of antibody-drug conjugates. Nat. Rev. Clin. Oncol. 21, 203\u2013223 https:\/\/doi.org\/10.1038\/s41571-023-00850-2 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1213_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04518-z","author":"MS Carlino","year":"2026","unstructured":"Carlino, M. S. et al. An anti-PMEL antibody-drug conjugate with a G(q\/1)(1) inhibitor payload in GNAQ\/GNA11-mutant melanomas: a phase 1 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-026-04518-z (2026).","journal-title":"Nat. Med."},{"key":"1213_CR79","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1101\/gad.180331.111","volume":"25","author":"T Shree","year":"2011","unstructured":"Shree, T. et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 25, 2465\u20132479 https:\/\/doi.org\/10.1101\/gad.180331.111 (2011).","journal-title":"Genes Dev."},{"key":"1213_CR80","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 https:\/\/doi.org\/10.1038\/nature13954 (2014).","journal-title":"Nature"},{"key":"1213_CR81","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","volume":"31","author":"B Pistilli","year":"2025","unstructured":"Pistilli, B. et al. Patritumab deruxtecan in HR+HER2\u2212 advanced breast cancer: a phase 2 trial. Nat. Med. 31, 3492\u20133503 https:\/\/doi.org\/10.1038\/s41591-025-03885-3 (2025).","journal-title":"Nat. Med."},{"key":"1213_CR82","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/1078-0432.CCR-23-1725","volume":"30","author":"Q Wei","year":"2024","unstructured":"Wei, Q. et al. Spatiotemporal quantification of HER2-targeting antibody-drug conjugate bystander activity and enhancement of solid tumor penetration. Clin. Cancer Res. 30, 984\u2013997 https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1725 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-191","volume":"9","author":"L Flamant","year":"2010","unstructured":"Flamant, L., Notte, A., Ninane, N., Raes, M. & Michiels, C. Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol. Cancer 9, 191 https:\/\/doi.org\/10.1186\/1476-4598-9-191 (2010).","journal-title":"Mol. Cancer"},{"key":"1213_CR84","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","volume":"20","author":"P Tarantino","year":"2023","unstructured":"Tarantino, P., Ricciuti, B., Pradhan, S. M. & Tolaney, S. M. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat. Rev. Clin. Oncol. 20, 558\u2013576 https:\/\/doi.org\/10.1038\/s41571-023-00783-w (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1213_CR85","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","volume":"59","author":"LP Stepan","year":"2011","unstructured":"Stepan, L. P. et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J. Histochem. Cytochem. 59, 701\u2013710 https:\/\/doi.org\/10.1369\/0022155411410430 (2011).","journal-title":"J. Histochem. Cytochem."},{"key":"1213_CR86","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","volume":"393","author":"J Cortes","year":"2025","unstructured":"Cortes, J. et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N. Engl. J. Med. 393, 1912\u20131925 https:\/\/doi.org\/10.1056\/NEJMoa2511734 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1213_CR87","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/OP-24-00806","volume":"22","author":"A Bardia","year":"2026","unstructured":"Bardia, A. et al. Q-TWiST analysis to assess benefit-risk of sacituzumab govitecan in previously treated patients with metastatic triple-negative breast cancer. JCO Oncol. Pract. 22, 793\u2013803 https:\/\/doi.org\/10.1200\/OP-24-00806 (2026).","journal-title":"JCO Oncol. Pract."},{"key":"1213_CR88","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","volume":"27","author":"ME Lacouture","year":"2022","unstructured":"Lacouture, M. E., Patel, A. B., Rosenberg, J. E. & O\u2019Donnell, P. H. Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist 27, e223\u2013e232 https:\/\/doi.org\/10.1093\/oncolo\/oyac001 (2022).","journal-title":"Oncologist"},{"key":"1213_CR89","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","volume":"31","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat. Med. 31, 3028\u20133036 https:\/\/doi.org\/10.1038\/s41591-025-03783-8 (2025).","journal-title":"Nat. Med."},{"key":"1213_CR90","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo, R. & Rich, J. R. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell 40, 1255\u20131263 https:\/\/doi.org\/10.1016\/j.ccell.2022.09.016 (2022).","journal-title":"Cancer Cell"},{"key":"1213_CR91","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","volume":"7","author":"P Tarantino","year":"2021","unstructured":"Tarantino, P. et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 7, 1873\u20131881 https:\/\/doi.org\/10.1001\/jamaoncol.2021.3595 (2021).","journal-title":"JAMA Oncol."},{"key":"1213_CR92","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1111\/cas.14686","volume":"111","author":"K Kumagai","year":"2020","unstructured":"Kumagai, K. et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 111, 4636\u20134645 https:\/\/doi.org\/10.1111\/cas.14686 (2020).","journal-title":"Cancer Sci."},{"key":"1213_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104212","volume":"193","author":"L Rached","year":"2024","unstructured":"Rached, L. et al. Antibody drug conjugates in older patients: state of the art. Crit. Rev. Oncol. Hematol. 193, 104212 https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104212 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1213_CR94","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40262-026-01633-5","volume":"65","author":"MJJ Lucassen","year":"2026","unstructured":"Lucassen, M. J. J. et al. Exposure-response relationships of antibody drug conjugates in solid tumours. Clin. Pharmacokinet. 65, 635\u2013645 https:\/\/doi.org\/10.1007\/s40262-026-01633-5 (2026).","journal-title":"Clin. Pharmacokinet."},{"key":"1213_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00467-1","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo, H. S. et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer 8, 98 https:\/\/doi.org\/10.1038\/s41523-022-00467-1 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"1213_CR96","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41571-018-0135-7","volume":"16","author":"B Zhang","year":"2019","unstructured":"Zhang, B. et al. Clinical potential of mass spectrometry-based proteogenomics. Nat. Rev. Clin. Oncol. 16, 256\u2013268 https:\/\/doi.org\/10.1038\/s41571-018-0135-7 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1213_CR97","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00128","volume":"9","author":"CJ Robbins","year":"2025","unstructured":"Robbins, C. J. et al. Quantitative multiplex immunofluorescence assay for trophoblast cell-surface antigen 2 and human epidermal growth factor receptor 2 expression in breast cancer: toward guiding patient selection for antibody-drug conjugate therapies. JCO Precis. Oncol. 9, e2500128 https:\/\/doi.org\/10.1200\/PO-25-00128 (2025).","journal-title":"JCO Precis. Oncol."},{"key":"1213_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43435-w","volume":"13","author":"F Rivest","year":"2023","unstructured":"Rivest, F. et al. Fully automated sequential immunofluorescence (seqIF) for hyperplex spatial proteomics. Sci. Rep. 13, 16994 https:\/\/doi.org\/10.1038\/s41598-023-43435-w (2023).","journal-title":"Sci. Rep."},{"key":"1213_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43458-x","volume":"14","author":"A Janesick","year":"2023","unstructured":"Janesick, A. et al. High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis. Nat. Commun. 14, 8353 https:\/\/doi.org\/10.1038\/s41467-023-43458-x (2023).","journal-title":"Nat. Commun."},{"key":"1213_CR100","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/pmic.201600203","volume":"16","author":"R Aebersold","year":"2016","unstructured":"Aebersold, R., Bensimon, A., Collins, B. C., Ludwig, C. & Sabido, E. Applications and developments in targeted proteomics: from SRM to DIA\/SWATH. Proteomics 16, 2065\u20132067 https:\/\/doi.org\/10.1002\/pmic.201600203 (2016).","journal-title":"Proteomics"},{"key":"1213_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202200238","volume":"23","author":"EL Boys","year":"2023","unstructured":"Boys, E. L., Liu, J., Robinson, P. J. & Reddel, R. R. Clinical applications of mass spectrometry-based proteomics in cancer: where are we? Proteomics 23, e2200238 https:\/\/doi.org\/10.1002\/pmic.202200238 (2023).","journal-title":"Proteomics"},{"key":"1213_CR102","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbaf040","volume":"9","author":"Y Li","year":"2026","unstructured":"Li, Y. et al. Spatial proteomics in precision medicine: technologies, bioinformatics, and translational applications. Precis. Clin. Med. 9, pbaf040 https:\/\/doi.org\/10.1093\/pcmedi\/pbaf040 (2026).","journal-title":"Precis. Clin. Med."},{"key":"1213_CR103","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41587-022-01302-5","volume":"40","author":"A Mund","year":"2022","unstructured":"Mund, A. et al. Deep visual proteomics defines single-cell identity and heterogeneity. Nat. Biotechnol. 40, 1231\u20131240 https:\/\/doi.org\/10.1038\/s41587-022-01302-5 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1213_CR104","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1158\/2159-8290.CD-24-1488","volume":"15","author":"Z Cai","year":"2025","unstructured":"Cai, Z. et al. Federated deep learning enables cancer subtyping by proteomics. Cancer Discov. 15, 1803\u20131818 https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1488 (2025).","journal-title":"Cancer Discov."},{"key":"1213_CR105","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1021\/pr501254j","volume":"14","author":"NJ Edwards","year":"2015","unstructured":"Edwards, N. J. et al. The CPTAC data portal: a resource for cancer proteomics research. J. Proteome Res. 14, 2707\u20132713 https:\/\/doi.org\/10.1021\/pr501254j (2015).","journal-title":"J. Proteome Res."},{"key":"1213_CR106","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41586-024-08280-5","volume":"636","author":"F He","year":"2024","unstructured":"He, F. et al. pi-HuB: the proteomic navigator of the human body. Nature 636, 322\u2013331 https:\/\/doi.org\/10.1038\/s41586-024-08280-5 (2024).","journal-title":"Nature"},{"key":"1213_CR107","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2967\/jnumed.121.262940","volume":"63","author":"JE Mortimer","year":"2022","unstructured":"Mortimer, J. E. et al. Use of 64Cu-DOTA-trastuzumab PET to predict response and outcome of patients receiving trastuzumab emtansine for metastatic breast cancer: a pilot study. J. Nucl. Med. 63, 1145\u20131148 https:\/\/doi.org\/10.2967\/jnumed.121.262940 (2022).","journal-title":"J. Nucl. Med."},{"key":"1213_CR108","doi-asserted-by":"publisher","DOI":"10.1177\/1536012118801223","volume":"17","author":"KS Carmon","year":"2018","unstructured":"Carmon, K. S. & Azhdarinia, A. Application of immuno-PET in antibody-drug conjugate development. Mol. Imaging 17, 1536012118801223 https:\/\/doi.org\/10.1177\/1536012118801223 (2018).","journal-title":"Mol. Imaging"},{"key":"1213_CR109","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.2967\/jnumed.124.268931","volume":"66","author":"A Mansur","year":"2025","unstructured":"Mansur, A. et al. Quantitative [89Zr]Zr-trastuzumab PET and diffusion- weighted MRI for characterization of metastatic HER2-positive breast cancer with PET\/MRI. J. Nucl. Med. 66, 1018\u20131026 https:\/\/doi.org\/10.2967\/jnumed.124.268931 (2025).","journal-title":"J. Nucl. Med."},{"key":"1213_CR110","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162148","author":"S Agarwal","year":"2023","unstructured":"Agarwal, S. et al. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI162148 (2023).","journal-title":"J. Clin. Invest."},{"key":"1213_CR111","doi-asserted-by":"publisher","unstructured":"Das, G. et al. Site-specific immune and stromal architecture drive resistance to trastuzumab deruxtecan in HER2+ metastatic breast cancer. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.05.23.654950 (2025).","DOI":"10.1101\/2025.05.23.654950"},{"key":"1213_CR112","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2025.11.011","volume":"44","author":"HN Tan","year":"2026","unstructured":"Tan, H. N., Elliott, M. J., Silverman, I. M., Siu, L. L. & Yap, T. A. Circulating tumor DNA as a biomarker in early phase clinical trials. Cancer Cell 44, 240\u2013247 https:\/\/doi.org\/10.1016\/j.ccell.2025.11.011 (2026).","journal-title":"Cancer Cell"},{"key":"1213_CR113","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"CR Merritt","year":"2020","unstructured":"Merritt, C. R. et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat. Biotechnol. 38, 586\u2013599 https:\/\/doi.org\/10.1038\/s41587-020-0472-9 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1213_CR114","doi-asserted-by":"publisher","first-page":"103798","DOI":"10.1016\/j.isci.2022.103798","volume":"25","author":"Z Cai","year":"2022","unstructured":"Cai, Z., Poulos, R. C., Liu, J. & Zhong, Q. Machine learning for multi-omics data integration in cancer. iScience 25, 103798 https:\/\/doi.org\/10.1016\/j.isci.2022.103798 (2022).","journal-title":"iScience"},{"key":"1213_CR115","doi-asserted-by":"publisher","first-page":"e1013012","DOI":"10.1371\/journal.pcbi.1013012","volume":"21","author":"H Benkirane","year":"2025","unstructured":"Benkirane, H. et al. Multimodal CustOmics: a unified and interpretable multi-task deep learning framework for multimodal integrative data analysis in oncology. PLoS Comput. Biol. 21, e1013012 https:\/\/doi.org\/10.1371\/journal.pcbi.1013012 (2025).","journal-title":"PLoS Comput. Biol."},{"key":"1213_CR116","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41746-020-00323-1","volume":"3","author":"N Rieke","year":"2020","unstructured":"Rieke, N. et al. The future of digital health with federated learning. NPJ Digit. Med. 3, 119 https:\/\/doi.org\/10.1038\/s41746-020-00323-1 (2020).","journal-title":"NPJ Digit. Med."},{"key":"1213_CR117","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1159\/000517438","volume":"99","author":"Y Ahmed","year":"2021","unstructured":"Ahmed, Y., Berenguer-Pina, J. J. & Mahgoub, T. The rise of the TROP2-targeting agents in NSCLC: new options on the horizon. Oncology 99, 673\u2013680 https:\/\/doi.org\/10.1159\/000517438 (2021).","journal-title":"Oncology"},{"key":"1213_CR118","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","volume":"31","author":"Y Ma","year":"2025","unstructured":"Ma, Y. et al. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial. Nat. Med. 31, 1949\u20131957 https:\/\/doi.org\/10.1038\/s41591-025-03600-2 (2025).","journal-title":"Nat. Med."},{"key":"1213_CR119","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","volume":"31","author":"DY Ruan","year":"2025","unstructured":"Ruan, D. Y. et al. The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial. Nat. Med. 31, 3037\u20133046 https:\/\/doi.org\/10.1038\/s41591-025-03781-w (2025).","journal-title":"Nat. Med."},{"key":"1213_CR120","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"DY Ruan","year":"2025","unstructured":"Ruan, D. Y. et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 26, 227\u2013238 https:\/\/doi.org\/10.1016\/S1470-2045(24)00636-3 (2025).","journal-title":"Lancet Oncol."},{"key":"1213_CR121","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12517","volume":"44","author":"DY Ruan","year":"2024","unstructured":"Ruan, D. Y., Wu, H. X., Meng, Q. & Xu, R. H. Development of antibody-drug conjugates in cancer: overview and prospects. Cancer Commun. 44, 3\u201322 https:\/\/doi.org\/10.1002\/cac2.12517 (2024).","journal-title":"Cancer Commun."},{"key":"1213_CR122","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO-24-01534","volume":"43","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Accelerating the future of oncology drug development: the role of consortia in the delivery of precision oncology early phase clinical trials. J. Clin. Oncol. 43, 735\u2013747 https:\/\/doi.org\/10.1200\/JCO-24-01534 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1213_CR123","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1016\/j.cell.2024.05.039","volume":"187","author":"SR Savage","year":"2024","unstructured":"Savage, S. R. et al. Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell 187, 4389\u20134407.e15 https:\/\/doi.org\/10.1016\/j.cell.2024.05.039 (2024).","journal-title":"Cell"},{"key":"1213_CR124","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1007\/s11427-014-4714-2","volume":"57","author":"N Li","year":"2014","unstructured":"Li, N. et al. Rapid development of proteomics in China: from the perspective of the Human Liver Proteome Project and technology development. Sci. China Life Sci. 57, 1162\u20131171 https:\/\/doi.org\/10.1007\/s11427-014-4714-2 (2014).","journal-title":"Sci. China Life Sci."},{"key":"1213_CR125","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.ccell.2022.06.010","volume":"40","author":"E Goncalves","year":"2022","unstructured":"Goncalves, E. et al. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell 40, 835\u2013849.e8 https:\/\/doi.org\/10.1016\/j.ccell.2022.06.010 (2022).","journal-title":"Cancer Cell"},{"key":"1213_CR126","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895\u20131902 https:\/\/doi.org\/10.1093\/annonc\/mdy263 (2018).","journal-title":"Ann. Oncol."},{"key":"1213_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67840-z","volume":"17","author":"K Borremans","year":"2025","unstructured":"Borremans, K. et al. Expression of antibody-drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue. Nat. Commun. 17, 1080 https:\/\/doi.org\/10.1038\/s41467-025-67840-z (2025).","journal-title":"Nat. Commun."},{"key":"1213_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113379","volume":"195","author":"C Bosi","year":"2023","unstructured":"Bosi, C. et al. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response. Eur. J. Cancer 195, 113379 https:\/\/doi.org\/10.1016\/j.ejca.2023.113379 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1213_CR129","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1074\/mcp.M500279-MCP200","volume":"4","author":"M Uhlen","year":"2005","unstructured":"Uhlen, M. et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell Proteom. 4, 1920\u20131932 https:\/\/doi.org\/10.1074\/mcp.M500279-MCP200 (2005).","journal-title":"Mol. Cell Proteom."},{"key":"1213_CR130","doi-asserted-by":"publisher","unstructured":"Chan, N. et al. Prospective assessment of a quantitative immunofluorescent assay to measure HER2 and TROP2 concentrations on a single tissue biopsy slide. Preprint at Research Square https:\/\/doi.org\/10.21203\/rs.3.rs-7785005\/v1 (2025).","DOI":"10.21203\/rs.3.rs-7785005\/v1"},{"key":"1213_CR131","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-26-0733","author":"J Liu","year":"2026","unstructured":"Liu, J. et al. Network integrated platform for clinical trials navigation from the New South Wales Early Phase Clinical Trials Alliance. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-26-0733 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR132","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO-25-01625","volume":"44","author":"E Alger","year":"2026","unstructured":"Alger, E. et al. International consensus-driven recommendations for patient-reported outcome research objectives in early phase dose-finding oncology trials: OPTIMISE-ROR. J. Clin. Oncol. 44, 709\u2013719 https:\/\/doi.org\/10.1200\/JCO-25-01625 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1213_CR133","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1158\/1078-0432.CCR-25-1918","volume":"31","author":"OO Okusanya","year":"2025","unstructured":"Okusanya, O. O. et al. FDA-AACR strategies for optimizing dosages for oncology drug products: early-phase trials using innovative trial designs and biomarkers. Clin. Cancer Res. 31, 4882\u20134890 https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1918 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR134","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.1158\/1078-0432.CCR-25-0098","volume":"31","author":"SS Shord","year":"2025","unstructured":"Shord, S. S. et al. FDA-AACR strategies for optimizing dosages for oncology drug products: selecting optimized dosages for registrational trials. Clin. Cancer Res. 31, 4891\u20134898 https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0098 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR135","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1158\/1078-0432.CCR-24-1836","volume":"30","author":"TA Yap","year":"2024","unstructured":"Yap, T. A. et al. Oncology combination drug development strategies for project Optimus. Clin. Cancer Res. 30, 5237\u20135241 https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1836 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1213_CR136","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1080\/10543406.2017.1379532","volume":"28","author":"X Wang","year":"2018","unstructured":"Wang, X., Zhou, J., Wang, T. & George, S. L. On enrichment strategies for biomarker stratified clinical trials. J. Biopharm. Stat. 28, 292\u2013308 https:\/\/doi.org\/10.1080\/10543406.2017.1379532 (2018).","journal-title":"J. Biopharm. Stat."},{"key":"1213_CR137","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","volume":"140","author":"AN Bartley","year":"2016","unstructured":"Bartley, A. N. et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch. Pathol. Lab. Med. 140, 1345\u20131363 https:\/\/doi.org\/10.5858\/arpa.2016-0331-CP (2016).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1213_CR138","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/modpathol.2016.116","volume":"29","author":"WA Schrijver","year":"2016","unstructured":"Schrijver, W. A. et al. Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer. Mod. Pathol. 29, 1460\u20131470 https:\/\/doi.org\/10.1038\/modpathol.2016.116 (2016).","journal-title":"Mod. Pathol."},{"key":"1213_CR139","unstructured":"US Food and Drug Administration. E16: biomarkers related to drug or biotechnology product development \u2014 context, structure and format of qualification submissions. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e16-biomarkers-related-drug-or-biotechnology-product-development-context-structure-and-format (2011)."},{"key":"1213_CR140","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00767","volume":"10","author":"V Subbiah","year":"2026","unstructured":"Subbiah, V., Oliver, T. K., Palma, J. & Kurzrock, R. Living guidelines for tumor-agnostic therapies: a pathway to next-generation cancer treatment. JCO Precis. Oncol. 10, e2500767 https:\/\/doi.org\/10.1200\/PO-25-00767 (2026).","journal-title":"JCO Precis. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01213-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01213-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01213-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:01:16Z","timestamp":1791532876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01213-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":140,"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01213-3","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"17 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L. has acted as a consultant of Greywolf Therapeutics, Starpharma and Taiho pharmaceuticals; has acted as a speaker for Dr Reddys and MSD; has received research funding from Abbvie, ALX Oncology, AVEO, Bayer, BMS, Beigene, Greywolf Therapeutics, Guardant360 Health, IDEAYA Biosciences, ImmVirX Biologics, Innovent Biologics, Medilink Therapeutics, Merus Biologics, MSD, Nested Therapeutics, OncoNano, Regeneron, Relay Therapeutics and Starpharma; and has received travel support from ImmVirx, Innovent Biologics and Starpharma. R.-H.X. has acted as a consultant for Astellas, AstraZeneca, Beigene, CPPC, Innovent, Junshi and MSD. V.S. has acted as a consultant and\/or advisor for Daiichi Sankyo, Helsinn Healthcare, Incyte Corporation, Jazz Pharmaceuticals, Loxo Oncology\/Eli Lilly, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics and R-Pharm US; has received research funding from AbbVie, Agensys, Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines Corporation, Boston Biomedical, Boston Pharmaceuticals, Celgene Corporation, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Incyte Corporation, Inhibrx, Loxo Oncology, MedImmune, MultiVir, NanoCarrier, National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche\/Genentech, Takeda, Turning Point Therapeutics, UT MD Anderson Cancer Center and Vegenics; has received travel support from ASCO, ESMO, Helsinn Healthcare, Incyte Corporation, Novartis and PharmaMar; and has a relationship with Medscape. D.L.R. has acted as a consultant and\/or advisor for Cell Signalling Technology, Cepheid, Danaher, Halda Bio, Hoffman-La Roche, Incendia, Multiplex Dx, NextCure, NucleAI and Regeneron; has received research funding from AbbVie, Cepheid, Leica\/Danaher, Lunit and Regeneron; and has received royalties from Rarecyte. B.P. has acted as a consultant of AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pierre Fabre, Puma and Seagen; has received research funding from AstraZeneca, Daiichi Sankyo, Gilead, MSD and Seagen; and has received travel support from AstraZeneca, Daiichi Sankyo, MSD, Novartis, Pfizer and Pierre Fabre. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}